Swiss biotech plans $134m IPO
This article was originally published in Scrip
Executive Summary
Popular Swiss biotechnology firm Molecular Partners plans to list its shares on the Swiss stock exchange in the fourth quarter of 2014 to raise around CHF125m ($134m). It is focused on the development of DARPins, non-antibody-based small proteins in which a variable region has been engineered for target binding.